Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 2,743 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $4.90, for a total transaction of $13,440.70. Following the sale, the chief executive officer now owns 1,207,365 shares of the company's stock, valued at approximately $5,916,088.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Michael Raab also recently made the following trade(s):
- On Monday, October 28th, Michael Raab sold 25,000 shares of Ardelyx stock. The stock was sold at an average price of $5.91, for a total transaction of $147,750.00.
- On Friday, October 11th, Michael Raab sold 7,500 shares of Ardelyx stock. The stock was sold at an average price of $6.01, for a total transaction of $45,075.00.
- On Thursday, September 26th, Michael Raab sold 3,000 shares of Ardelyx stock. The stock was sold at an average price of $6.07, for a total transaction of $18,210.00.
- On Wednesday, September 11th, Michael Raab sold 35,000 shares of Ardelyx stock. The stock was sold at an average price of $5.61, for a total transaction of $196,350.00.
- On Tuesday, August 27th, Michael Raab sold 7,500 shares of Ardelyx stock. The stock was sold at an average price of $6.22, for a total transaction of $46,650.00.
- On Tuesday, August 20th, Michael Raab sold 32,225 shares of Ardelyx stock. The stock was sold at an average price of $5.86, for a total transaction of $188,838.50.
Ardelyx Price Performance
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
From Colonial Metals | Ad
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code…
And since then…
"In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Get Your Free Gold Guide
ARDX opened at $4.59 on Wednesday. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -15.30 and a beta of 0.92. The company has a quick ratio of 3.87, a current ratio of 4.03 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average price of $6.01 and a 200-day moving average price of $6.29. Ardelyx, Inc. has a twelve month low of $3.49 and a twelve month high of $10.13.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on ARDX. Citigroup reduced their price objective on shares of Ardelyx from $12.00 to $10.00 and set a "buy" rating for the company in a report on Monday, November 4th. HC Wainwright cut shares of Ardelyx from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $11.00 to $5.50 in a report on Monday. StockNews.com upgraded shares of Ardelyx from a "sell" rating to a "hold" rating in a report on Wednesday, July 31st. Finally, Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Ardelyx in a research report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Ardelyx presently has an average rating of "Moderate Buy" and a consensus target price of $10.42.
Check Out Our Latest Analysis on ARDX
Hedge Funds Weigh In On Ardelyx
Several large investors have recently modified their holdings of ARDX. World Equity Group Inc. grew its stake in Ardelyx by 15.4% during the second quarter. World Equity Group Inc. now owns 18,402 shares of the biopharmaceutical company's stock valued at $136,000 after acquiring an additional 2,453 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Ardelyx by 1,026.3% during the second quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 3,233 shares in the last quarter. ProShare Advisors LLC grew its stake in Ardelyx by 8.9% during the first quarter. ProShare Advisors LLC now owns 57,729 shares of the biopharmaceutical company's stock valued at $421,000 after acquiring an additional 4,735 shares in the last quarter. Aigen Investment Management LP grew its stake in Ardelyx by 29.4% during the third quarter. Aigen Investment Management LP now owns 23,510 shares of the biopharmaceutical company's stock valued at $162,000 after acquiring an additional 5,346 shares in the last quarter. Finally, Values First Advisors Inc. grew its stake in Ardelyx by 14.6% during the third quarter. Values First Advisors Inc. now owns 46,282 shares of the biopharmaceutical company's stock valued at $319,000 after acquiring an additional 5,890 shares in the last quarter. Hedge funds and other institutional investors own 58.92% of the company's stock.
About Ardelyx
(
Get Free Report)
Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
